| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Achieving equitable care in pulmonary embolism: exploring the potential of pulmonary embolism response teams
|
Sul, Lidiya V.
|
|
|
9 |
1 |
p. 166-168
|
article
|
| 2 |
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
|
Brown, Fiona C.
|
|
|
9 |
1 |
p. 127-131
|
article
|
| 3 |
AIHA and rituximab: time for Pneumocystis prophylaxis?
|
Hansen, Dennis Lund
|
|
|
9 |
1 |
p. 229-230
|
article
|
| 4 |
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
|
Castaño-Díez, Sandra
|
|
|
9 |
1 |
p. 39-53
|
article
|
| 5 |
Back from (BTKi) holiday
|
Brander, Danielle M.
|
|
|
9 |
1 |
p. 222-223
|
article
|
| 6 |
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
|
Valtis, Yannis K.
|
|
|
9 |
1 |
p. 151-161
|
article
|
| 7 |
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
|
Jeremy, Erin
|
|
|
9 |
1 |
p. 1-14
|
article
|
| 8 |
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow
|
Zhao, Kai
|
|
|
9 |
1 |
p. 209-221
|
article
|
| 9 |
Control of antigen-independent T-cell migration after HSCT
|
Koyama, Motoko
|
|
|
9 |
1 |
p. 207-208
|
article
|
| 10 |
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
|
Autore, Francesco
|
|
|
9 |
1 |
p. 162-165
|
article
|
| 11 |
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
|
Avigan, Zachary M.
|
|
|
9 |
1 |
p. 202-206
|
article
|
| 12 |
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment
|
Ren, Kehan
|
|
|
9 |
1 |
p. 54-65
|
article
|
| 13 |
Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid
|
Sim, Derek S.
|
|
|
9 |
1 |
p. 180-191
|
article
|
| 14 |
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
|
Lachey, Jennifer
|
|
|
9 |
1 |
p. 193-201
|
article
|
| 15 |
Factor XI inhibitors: a new class of anticoagulants
|
Connors, Jean M.
|
|
|
9 |
1 |
p. 192
|
article
|
| 16 |
Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel
|
Mirza, Adil
|
|
|
9 |
1 |
p. 29-38
|
article
|
| 17 |
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE
|
Camus, Vincent
|
|
|
9 |
1 |
p. 101-115
|
article
|
| 18 |
Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
|
Ferri, Grace M.
|
|
|
9 |
1 |
p. 78-88
|
article
|
| 19 |
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.
|
|
|
|
9 |
1 |
p. 169
|
article
|
| 20 |
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
|
Chen, Lucia Y.
|
|
|
9 |
1 |
p. 176-179
|
article
|
| 21 |
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study
|
Maese, Luke
|
|
|
9 |
1 |
p. 66-77
|
article
|
| 22 |
Respiratory phenotype and health care utilization patterns by adults with sickle cell disease
|
Agawu, Atu
|
|
|
9 |
1 |
p. 143-150
|
article
|
| 23 |
Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study
|
Zadro, Yoann
|
|
|
9 |
1 |
p. 231-238
|
article
|
| 24 |
Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow
|
Lykins, Joshua
|
|
|
9 |
1 |
p. 15-28
|
article
|
| 25 |
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
|
Bajwa, Amneet
|
|
|
9 |
1 |
p. 170-175
|
article
|
| 26 |
Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
|
Espinosa-Cotton, Madelyn
|
|
|
9 |
1 |
p. 116-126
|
article
|
| 27 |
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding
|
Sims, Matthew C.
|
|
|
9 |
1 |
p. 132-142
|
article
|
| 28 |
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
|
Shanafelt, Tait D.
|
|
|
9 |
1 |
p. 224-228
|
article
|
| 29 |
Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
|
Pechlivani, Nikoletta
|
|
|
9 |
1 |
p. 89-100
|
article
|
Journal description